Form 4: Nurix Therapeutics CFO Hans van Houte Reports Stock Transactions

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• On April 30, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• Van Houte acquired 2,886 shares and 2,000 shares of common stock through the vesting of RSUs.
• Simultaneously, 1,387 shares were disposed of at a weighted average price of $12.0422 to cover tax withholding obligations related to the vesting of the RSUs.
• Following these transactions, Van Houte beneficially owns 71,832 shares of common stock and 36,203 restricted stock units.
• The sales were mandated by Nurix Therapeutics' equity incentive plans to cover tax obligations.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment, as it reflects standard compensation practices and tax obligations.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates the CFO's transactions related to vested stock and tax obligations, which is a common practice.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but it is primarily related to the executive's compensation and tax obligations.
• Employees holding RSUs may be interested in the vesting schedule and tax implications.

Key Dates